KROS
Price
$18.00
Change
-$1.42 (-7.31%)
Updated
Dec 17 closing price
71 days until earnings call
XENE
Price
$40.87
Change
-$0.41 (-0.99%)
Updated
Dec 18, 11:15 AM (EDT)
70 days until earnings call
Ad is loading...

KROS vs XENE

Header iconKROS vs XENE Comparison
Open Charts KROS vs XENEBanner chart's image
Keros Therapeutics
Price$18.00
Change-$1.42 (-7.31%)
Volume$2.25M
CapitalizationN/A
Xenon Pharmaceuticals
Price$40.87
Change-$0.41 (-0.99%)
Volume$100
CapitalizationN/A
KROS vs XENE Comparison Chart
Loading...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KROS vs. XENE commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and XENE is a Buy.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (KROS: $18.00 vs. XENE: $41.28)
Brand notoriety: KROS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KROS: 249% vs. XENE: 68%
Market capitalization -- KROS: $786.65M vs. XENE: $3.15B
KROS [@Biotechnology] is valued at $786.65M. XENE’s [@Biotechnology] market capitalization is $3.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • KROS’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than KROS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • KROS’s TA Score: 5 bullish, 5 bearish.
  • XENE’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, XENE is a better buy in the short-term than KROS.

Price Growth

KROS (@Biotechnology) experienced а -72.85% price change this week, while XENE (@Biotechnology) price change was -1.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.45%, and the average quarterly price growth was +4.23%.

Reported Earning Dates

KROS is expected to report earnings on Feb 27, 2025.

XENE is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.15B) has a higher market cap than KROS($787M). XENE YTD gains are higher at: -10.378 vs. KROS (-54.728). KROS has higher annual earnings (EBITDA): -185.94M vs. XENE (-252.74M). XENE has more cash in the bank: 654M vs. KROS (531M). XENE has less debt than KROS: XENE (9.79M) vs KROS (19.3M). KROS has higher revenues than XENE: KROS (651K) vs XENE (0).
KROSXENEKROS / XENE
Capitalization787M3.15B25%
EBITDA-185.94M-252.74M74%
Gain YTD-54.728-10.378527%
P/E RatioN/AN/A-
Revenue651K0-
Total Cash531M654M81%
Total Debt19.3M9.79M197%
FUNDAMENTALS RATINGS
XENE: Fundamental Ratings
XENE
OUTLOOK RATING
1..100
71
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
PROFIT vs RISK RATING
1..100
12
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KROSXENE
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 9 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEIRX7.27N/A
N/A
MassMutual International Eq R4
TLWCX21.45N/A
N/A
Nuveen Large Cap Responsible Eq A
RRSCX27.17-0.07
-0.26%
Russell Inv Global Real Estate Secs C
CEUEX56.22-0.20
-0.35%
American Funds Europacific Growth 529E
FDEGX75.35-0.93
-1.22%
Fidelity Growth Strategies

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INZY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
-7.31%
INZY - KROS
43%
Loosely correlated
-2.65%
AXON - KROS
43%
Loosely correlated
-2.09%
XENE - KROS
42%
Loosely correlated
-0.07%
TFFP - KROS
40%
Loosely correlated
N/A
RAPT - KROS
39%
Loosely correlated
-4.56%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with PLRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-0.07%
PLRX - XENE
48%
Loosely correlated
+4.74%
PGEN - XENE
47%
Loosely correlated
+2.46%
RCKT - XENE
47%
Loosely correlated
+1.36%
CRNX - XENE
46%
Loosely correlated
+1.35%
KYMR - XENE
44%
Loosely correlated
-1.76%
More